| # | Company | Location | Employees | Total Funding | Last Round | Last Funded |
|---|---|---|---|---|---|---|
| 1 |
Insilico Medicine
Insilico Medicine develops an AI platform for drug development to treat cancer a…
|
Cambridge | 101 - 250 | $624.3M | Series E | 2025-03-13 |
| 2 |
Alvotech
Alvotech is a biotechnology company that specializes in making biosimilars to cr…
|
Reykjav├¡k | — | $2.0B | Post Ipo Debt | 2025-12-31 |
| 3 |
Nuclera
Nuclera offers a protein prototyping system to accelerate drug discovery by maki…
|
Cambridge | — | $157.8M | Series C | 2026-01-13 |
| 4 |
Neuralink
Neuralink is a neurotechnology company that focuses on developing brain-computer…
|
Fremont | 251 - 500 | $1.3B | Series Unknown | 2025-07-07 |
| 5 |
Juvena Therapeutics
Juvena Therapeutics develops tissue-restorative biologics to address chronic mus…
|
Palo Alto | 11 - 50 | $113.2M | Series B | 2026-01-12 |
| 6 |
Catalio Capital Management
Catalio Capital Management is a venture capital firm that invests in breakthroug…
|
New York | 11 - 50 | — | Private Equity | 2023-10-17 |
| 7 |
Parabilis Medicines
Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specialize…
|
Cambridge | 101 - 250 | $835.3M | Series F | 2026-01-08 |
| 8 |
Alumis
Alumis is a precision medicine company focused on the discovery, development and…
|
San Francisco | 101 - 250 | $917.2M | Post Ipo Equity | 2026-01-07 |
| 9 |
Mediar Therapeutics
Mediar is a pre-clinical stage biotechnology company developing therapeutics for…
|
Cambridge | 11 - 50 | $181.0M | Series B | 2026-01-07 |
| 10 |
Tempus
Tempus develops AI-enabled precision medicine technology that supports clinical …
|
Chicago | 1K - 5K | $2.3B | Post Ipo Debt | 2025-06-30 |
| 11 |
Ventyx Biosciences
Ventyx is a biopharmaceutical company focused on advancing oral therapies for pa…
|
San Diego | 101 - 250 | $468.6M | Post Ipo Equity | 2024-09-23 |
| 12 |
Rakuten Medical
Rakuten Medical is a biotechnology company developing investigational cancer the…
|
San Diego | 101 - 250 | $837.6M | Corporate Round | 2026-04-02 |
| 13 |
Ceribell
Ceribell focuses on making electroencephalography accessible, efficient, and cos…
|
Mountain View | 251 - 500 | $171.0M | Series C | 2022-09-21 |
| 14 |
BioAge Labs
BioAge Labs is a clinical-stage biotechnology company that develops therapeutics…
|
Richmond | 51 - 100 | $408.9M | Post Ipo Equity | 2026-01-21 |
| 15 |
BrainCo
BrainCo develops brain-computer interface technologies for wellness and educatio…
|
Somerville | 101 - 250 | $1.2B | Series Unknown | 2026-01-06 |
| 16 |
Diagonal Therapeutics
Diagonal Therapeutics is a biotechnology startup that develops targeted therapie…
|
Watertown | 11 - 50 | $253.0M | Series B | 2026-01-08 |
| 17 |
Alamar Biosciences
Alamar Biosciences develops technologies for the detection and treatment of canc…
|
Fremont | 51 - 100 | $282.0M | Convertible Note | 2026-01-11 |
| 18 |
Corsera Health
Corsera Health develops preventive RNA interference medicines that reduces cardi…
|
Boston | 11 - 50 | $130.0M | Series A | 2026-01-07 |
| 19 |
Aktis Oncology
Aktis Oncology is a biotechnology company that designs and develops novel class …
|
Boston | 51 - 100 | $331.0M | Series B | 2024-09-30 |
| 20 |
Freenome
Freenome is a biotechnology company developing blood tests for early cancer dete…
|
South San Francisco | 251 - 500 | $1.5B | Corporate Round | 2025-11-17 |
| 21 |
Exciva
Exciva develops clinical-stage biopharmaceutical therapies focused on addressing…
|
Heidelberg | 1 - 10 | $69.8M | Series B | 2026-01-20 |
| 22 |
BillionToOne
BillionToOne is a precision diagnostics company that focuses on genetic testing …
|
Menlo Park | 501 - 1K | $425.9M | Series D | 2024-06-21 |
| 23 |
Century Therapeutics
Century Therapeutics is a biotechnology company that develops cell therapies for…
|
Philadelphia | 101 - 250 | $755.0M | Post Ipo Equity | 2026-01-08 |
| 24 |
Ukko
Ukko is a biotechnology company focused on developing immunotherapies for the tr…
|
Palo Alto | 11 - 50 | $92.7M | Series C | 2026-01-08 |
| 25 |
Caris Life Sciences
Caris Life Sciences develops molecular profiling and AI-driven technologies to s…
|
Irving | 1K - 5K | $1.9B | Private Equity | 2025-04-07 |
| 26 |
Loyal
Loyal is a clinical-stage veterinary medicine company dedicated to extending the…
|
San Francisco | 101 - 250 | $237.1M | Series C | 2026-02-11 |
| 27 |
Invivyd
Invivyd develops antibodies to transcend the limitations of the human immune sys…
|
Waltham | 101 - 250 | $678.5M | Post Ipo Equity | 2025-11-17 |
| 28 |
Femasys
Femasys engages in R&D and manufacture of medical devices for women's healthcare…
|
Suwanee | 11 - 50 | $95.3M | Post Ipo Debt | 2025-11-03 |
| 29 |
Precede Biosciences
Precede Biosciences is a biotechnology company that provides a blood-based appro…
|
Boston | 11 - 50 | $140.5M | Series B | 2026-01-12 |
| 30 |
b.well Connected Health
B.well Connected Health is a digital health platform that provides individuals w…
|
Baltimore | 101 - 250 | $118.8M | Debt Financing | 2025-07-30 |
| 31 |
FibroBiologics
FibroBiologics is a regenerative medicine company developing an innovative solut…
|
Houston | 11 - 50 | $145.2M | Post Ipo Equity | 2026-03-31 |
| 32 |
Myome
Myome helps identify genes that cause disease and act based on leading science.
|
Palo Alto | 11 - 50 | $23.0M | Series Unknown | 2025-12-11 |
| 33 |
Parse Biosciences
Parse Biosciences is a biotechnology startup company that develops single-cell s…
|
Seattle | 101 - 250 | $100.0M | Series C | 2023-12-14 |
| 34 |
Isomorphic Labs
Isomorphic Labs provides AI-driven solutions for drug discovery and development.
|
London | 101 - 250 | $601.7M | Series A | 2025-03-31 |
| 35 |
Profusa
PROFUSA is a medical devices company creating tissue-integrated sensors for chro…
|
San Francisco | 51 - 100 | $99.9M | Post Ipo Debt | 2025-07-14 |
| 36 |
FineHeart
FineHeart is a medical device company
|
Bordeaux | 11 - 50 | $146.8M | Grant | 2026-01-08 |
| 37 |
Converge Bio
Converge Bio integrates Generative AI with biological data.
|
Wilmington | 11 - 50 | $30.5M | Series A | 2026-01-13 |
| 38 |
Tessera Therapeutics
Tessera Therapeutics is a biotechnology company pioneering Gene Writing™ to driv…
|
Cambridge | 251 - 500 | $773.1M | Grant | 2026-03-23 |
| 39 |
Variant Bio
Variant Bio is leveraging the power of human genetic diversity to discover new t…
|
Seattle | 11 - 50 | $129.7M | Series B | 2021-11-09 |
| 40 |
Beacon Therapeutics
Beacon Therapeutics is a biotechnology company that develops treatments to prese…
|
Alachua | 101 - 250 | $365.1M | Series C | 2026-01-08 |
| 41 |
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutic…
|
San Francisco | 1 - 10 | $142.0M | Series B | 2025-12-16 |
| 42 |
AirNexis Therapeutics
AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive …
|
Palo Alto | — | $200.0M | Series A | 2026-01-09 |
| 43 |
Heartflow
Heartflow is a medical technology company that provides various methods of diagn…
|
Mountain View | 501 - 1K | $890.7M | Convertible Note | 2025-03-26 |
| 44 |
Kyverna Therapeutics
Kyverna Therapeutics is pioneering a new class of therapies and cures for seriou…
|
Berkeley | 101 - 250 | $295.0M | Post Ipo Equity | 2025-12-17 |
| 45 |
Erasca
Erasca is a developer of oncology drugs intended to provide precision oncology o…
|
San Diego | 101 - 250 | $854.0M | Post Ipo Equity | 2026-01-21 |
| 46 |
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery,…
|
Cambridge | 1K - 5K | $4.5B | Post Ipo Debt | 2025-09-09 |
| 47 |
Parallel Health
Parallel is a next-generation skin health company providing derm telehealth, ski…
|
San Francisco | 1 - 10 | $1.9M | Grant | 2022-09-20 |
| 48 |
Bactolife
Bactolife is a biotechnology company that develops biological solutions to suppo…
|
Lyngby | 11 - 50 | $81.5M | Series B | 2026-01-06 |
| 49 |
Lisata Therapeutics
Lisata Therapeutics is a clinical-stage biopharmaceutical company.
|
Basking Ridge | 11 - 50 | $165.6M | Grant | 2021-05-12 |
| 50 |
BlueNalu
BlueNalu is a cellular aquaculture company that provides healthy and safe seafoo…
|
San Diego | 11 - 50 | $132.2M | Convertible Note | 2025-12-29 |